About CHRS Dividend Returns
Coherus Oncology, Inc. (CHRS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of CHRS over the past year?
Coherus Oncology, Inc. (CHRS) delivered a return of 50.45% over the past year. Since CHRS does not currently pay dividends, the total return equals the price-only return.
Q2How much would $10,000 invested in CHRS be worth today?
A $10,000 investment in Coherus Oncology, Inc. one year ago would be worth $15,045 today, representing a gain of $5,045.
Q3Does CHRS pay dividends?
Coherus Oncology, Inc. (CHRS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CHRS, the total return equals the price-only return.
Q4Did CHRS beat the S&P 500?
Yes, Coherus Oncology, Inc. (CHRS) outperformed the S&P 500 by 35.00 percentage points over the past year. CHRS delivered a total return of 50.45%, compared to the S&P 500's 15.45%. This 35.00pp alpha means investors in CHRS earned more than a passive S&P 500 index fund.
Q5What is CHRS's worst drawdown?
Coherus Oncology, Inc. (CHRS) experienced a maximum drawdown of -39.56% over the past year, declining from its peak on 2025-10-09 to its trough on 2025-11-20. The stock recovered to its prior peak by 2026-01-23. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is CHRS's long-term total return over 10, 20, or 30 years?
Coherus Oncology, Inc. (CHRS) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -88.2% (-19.3% CAGR) — $10,000 would have grown to $1,177. Over 20 years: -86.8% total return (-9.6% CAGR) — $10,000 → $1,324. Over 30 years: -86.8% total return (-6.5% CAGR) — $10,000 → $1,324. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was CHRS's best and worst year?
Coherus Oncology, Inc.'s best calendar year was 2019 with a total return of 97.4%. Its worst year was 2017 with a total return of -68.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 166.0 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).